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Abstract 
 
The controversy over whether vaccine-targeted HPV types will be replaced by other oncogenic, 
non-vaccine-targeted types remains unresolved. This is in part because little is known about the 
ecology of HPV types. Patient data has been interpreted to suggest independence or facilitative 
interactions between types and therefore replacement is believed to be unlikely. With a novel 
mathematical model, we investigated which HPV type interactions and their immune responses 
gave qualitatively similar patterns frequently observed in patients. To assess the possibility of 
type replacement, vaccination was added to see if non-vaccine-targeted types increased their 
‘niche’. Our model predicts that independence and facilitation are not necessary for the 
coexistence of types inside hosts, especially given the patchy nature of HPV infection. In fact, 
independence and facilitation inadequately represented co-infected patients. We found that some 
form of competition is likely in natural co-infections.  Hence, non-vaccine-targeted types that are 
not cross-reactive with the vaccine could spread to more patches and can increase their viral load 
in vaccinated hosts. The degree to which this happens will depend on replication and patch 
colonization rates. Our results suggest that independence between types could be a fallacy, and 
so without conclusively untangling HPV within-host ecology, type replacement remains 
theoretically viable. More ecological thinking is needed in future studies. 
 
 
Keywords: HPV, within-host ecology, strain replacement, strain interactions, metapopulation 
dynamics. 
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Introduction 
 
  Infection by Human Papillomavirus (HPV) is responsible for approximately 270,000 
cervical cancer deaths and roughly 97,000 cases of other cancers (e.g. anal, oropharyngeal) 
globally every year (Tota et al., 2011b). The significance of finding a virus as a causal agent to 
cancer cannot be understated since it permits us to prevent cancers with vaccines. Two vaccines, 
Cervarix ® and Gardasil ®, are used to prevent cancer by the two most common oncogenic high-
risk (HR) HPV types, namely, HPV-16 and -18. Controversy has surfaced around the strain 
specificity of the HPV vaccines, since other strain-specific vaccines have led to strain 
replacement (reviews (Gandon and Day, 2008; Martcheva et al., 2008)), such that strains not 
targeted by the vaccine increase in prevalence over time. Thus, the removal of these vaccine-
targeted types (vaccine types) could lead to an increase of other HR types not targeted by the 
vaccine (non-vaccine types). Alarmingly, a recent increase in prevalence of non-vaccine types 
was measured in vaccinated young women and in the study population (Kahn et al., 2012) -- a 
potential first warning that type replacement in HPV is occurring. 
Whether a population will expand its niche once another population is removed from a 
shared environment is fundamentally an ecological question. Indeed, predicting the outcome of 
removing the vaccine types, HPV-16 and -18, first requires understanding how HPV types 
interact ecologically during co-infections. In fact, untangling HPV type interactions could also 
help us understand disease progression (Spinillo et al., 2009). Yet, despite these important 
reasons, little is known about HPV type interactions and ecology. Here, we analyze this problem 
using an ecological framework and we consider the impact the vaccine has on the within-host 
ecology of HPV. 
5 
 
The only type-type interaction that has been clearly demonstrated is that some types 
interact via the immune response. Types phylogenetically related to HPV-16 (i.e. types in the 
species α-9) have a negative effect on its viral load (Williams et al., 2002; Xi et al., 2009). 
Likewise, types with similar epitopes on the vaccine-targeted capsid protein, L1, to those of the 
vaccine-types HPV-16 and -18 (Christensen and Bounds, 2010) experience some cross-
protection by the vaccine (HPV-31, -33, -45, -51 (Wheeler et al., 2012)). Together these studies 
demonstrate ‘immune-mediated apparent competition’ (Mideo, 2009) between some related 
types.  
Of all HPV infections 30-50% are multiple infections and, concurrent acquisition 
(presumably due to co-transmission) of various types is common (Plummer et al., 2011; Thomas 
et al., 2001). How such a large diversity of HPV types can regularly coexist inside hosts is not 
understood and has led to speculations of facilitative or ‘synergistic’ interactions between types 
(Elbasha and Galvani, 2005; Woodman et al., 2007) or that types are independent (Plummer et 
al., 2007; Stanley et al., 2006). In contrast, there is some evidence that HPV types may compete 
for resources (McLaughlin-Drubin and Meyers, 2004), either by co-infecting the same cells and 
competing for intra-cellular resources or by competing for cells via blocking cell entry. Overall, 
then, the picture as to how HPV types interact inside hosts is not clear. Clarifying how types 
interact should have predictive power. Two prior mathematical transmission models (Elbasha 
and Galvani, 2005; Poolman et al., 2008) found that the occurrence of type replacement will 
depend on whether types compete or facilitate, and so, their results hinge on the assumptions 
about within-host interactions. However, the within-host interactions were a black-box in these 
models, and they continue to be so today.  
Based on common interpretations of epidemiological data, there are two main hypotheses 
of how HPV types interact: facilitation or independence. Support for the former comes from 
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studies that have found that seropositive patients are more likely to become seropositive with 
another type (Dillner et al., 2010). The latter is supported by several studies that have not found 
patterns of clustering at the epidemiological level (reviews (Dillner et al., 2010; Tota et al., 
2013)). It is reasoned that the random distribution of types at the population level implies that 
within hosts there is ‘no competition’ or ‘no interactions’ (Garnett and Waddell, 2000; Tota et 
al., 2013) and that competition between types should be detectable epidemiologically because 
types that compete would not be found together in co-infections  (Kaasila et al., 2009; Palmroth 
et al., 2012). Underlying this is the concept of ‘superinfection’ (Levin and Pimentel, 1981; 
Nowak and May, 1994), where a host already infected by one strain can become infected by 
another but due to strong within-host competition the new strain quickly excludes the other, thus 
implying that strains cannot coexistence inside hosts, i.e. co-infections are not possible. Given 
that independence is the most accepted hypothesis, it is believed that the vaccines will not affect 
non-vaccine types (Schiller and Lowy, 2012). 
Here we test these hypothesized interactions by investigating which interaction scenario 
behaves most like HPV co-infections. Using a within-host model we investigated independence, 
facilitation, resource competition (a form of competition that has been largely ignored) and their 
combinations. This within-host approach allows us to look inside the black-box by explicitly 
considering the behaviour of different possible interactions inside unvaccinated and vaccinated 
hosts.  
We found that within-host ecological interactions that are not solely independent or 
facilitative can readily give rise to observed co-infection dynamics. Hence, we caution that the 
current interpretations of epidemiological data require more support. 
Methods 
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Model 
HPV is a small double stranded DNA virus that infects epithelial cells. As a non-lytic 
virus, HPV’s replication cycle is linked to the life cycle of the host cell, meaning that HPV must 
infect basal epithelial cells (Kines et al., 2009; Schiller et al., 2010) and follow them up through 
the epithelial column until they die naturally at the surface of the skin (Doorbar et al., 2012). 
Therefore, new virions are not released until the cells die at the surface (Fig. 1a .i) and HPV 
needs abrasions in the skin to reach and infect new basal epithelial cells (Fig. 1a .ii)(Doorbar, 
2005; Doorbar et al., 2012). This spatial restriction implies that HPV infections are localized, 
which leads to characteristic lesions, or warts (Doorbar, 2005). HPV infection should thus be 
conceptualized as occurring in various “patches” distributed across space (Fig. 1a).   
We developed a novel patch model that represents HPV co-infections that is based on the 
Levins metapopulation models from ecology (Levins, 1969), which is a useful framework for 
understanding plant population dispersion and interactions (Husband and Barrett, 1996). These 
models describe patches as areas where plants are immobilized and seeds are carried by wind or 
pollinators to new patches. Here, patches are localized areas of the epithelium that are infected 
by one or multiple HPV types and that produce free virions (analogous to seeds). Note that if 
they are infected with HR types these patches become lesions over time.  
Apart from patches, our model also includes an explicit cellular immune response and an 
implicit humoral response. A cellular immune response, i.e. an infiltration of cytotoxic T-cells 
(CTL) is needed to clear lesions (Stanley, 2006). The equations of our model represent the 
population of CTL, Z, the patches infected with HPV-16, P16, patches with another HR non-
vaccine type, Phr, co-infected patches, Pco, and the proportion of empty patches, Po. The model, 
which is graphically represented in Fig. 1b, is        
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where the i represents 16 or hr depending on the case in question, i.e. which type has the CTL 
mounted against. Here, CTL proliferate at rate γ, die at rate μ, and clear a patch with type i at rate 
αi. Singly infected patches produce virions of type i at rate fi, while co-infected patches do so at a 
rate fico. The establishment rate of the non-vaccine type into patches already with HPV-16, ε, can 
be different from the rest of the establishment rates, e. The humoral response (via neutralizing 
antibodies) decreases the ability of free virions to infect new patches. Therefore, we approximate 
this effect by decreasing the establishment of patches, e and ε, by dividing them by the 
parameters whr or w16. See Appendix A for derivations and other details, such as how we 
adjusted this model to represent different interaction scenarios. 
This patch approach is representative of HPV infections that infect layered squamous cell 
epithelium, regardless of location in the body. However, this framework does not apply to HPV 
infections of transformation zones where the basal cells are exposed at the surface. For these, a 
homogeneous mixing model of individual cells might be more suitable. Also note that this model 
assumes re-entry of virions and not infection by a new contact episode. We believe that when an 
abrasion is formed, re-entry is more likely than infection by a new sexual contact event given 
that virions on the surface are more likely to be from the infected cells then from a one-time 
inoculum.  
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Model Parameterization 
We obtained estimates for CTL parameters from the biomedical literature (μ and γ from 
(de Boer et al., 2001)). CTL killing rates specific for HPV were not found in the literature, and 
therefore, the killing rate, α, was varied between 0 and 0.5 day-1 which is consistent with 
estimates by (Asquith et al., 2006) and is under the lower bound of (Yates et al., 2007). CTL 
killing rates of HPV infected cells should theoretically be slower than those measured in HIV 
infections because of limited access to cells inside the epithelial layers. Given the novelty of this 
model and the lack of HPV kinetics studies, we could not obtain point estimates for other 
parameters, so we created plausible ranges consistent with the known natural history of HPV 
(Table A.1). 
 
Analysis: Interaction scenarios 
To investigate competing hypotheses, parameters were varied to represent possible 
combinations of interactions. To consider resource competition, we included co-infected patches 
where types interact by infecting the same cells and thus have a reciprocal negative effect on 
each other’s replication rates (f 16co < f 16 and/or f hrco <  f hr). In the case of no intra-patch 
competition both co-infected patches and singly infected patches produced virions at the same 
rate (f 16co = f 16 and f hrco = f hr). The proposed mechanism for facilitation is that previous 
infection of one type allows another to establish in the same part of the epithelium. Therefore, to 
include facilitation we varied the establishment rate, ε. In the no facilitation scenario, the 
establishment rate into patches with HPV-16, ε, was set to equal that into patches with the same 
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type (ε = e = 1). To consider independence, we used model A.3 (Appendix) which does not have 
competition for patches, intra-patch competition or facilitation.  Finally, we also considered both 
competition and facilitation together and, in the vaccinated case, competition only for patches 
(model A.2, Appendix). 
 
Analysis: Immunity scenarios 
Natural immunity  
HPV is a very poor immunogen, so we assumed the adaptive response was absent during the first 
10 months of infection (Stanley, 2006), and then it attacked either HPV-16 (equation Z grows 
with respect to P16 and α16 > αhr) or the other type first (equation Z grows with respect to Phr and 
αhr > α16). Cross-reactivity was varied from none (αhr = 0 or α16 = 0) to full cross-immunity.  
Since antibodies play little to no role in natural immunity against HPV (many hosts during 
natural HPV infection do not seroconvert (Baseman and Koutsky, 2005; Carter et al., 2011)) we 
set whr= w16 = 1 for the natural cases. With the natural cases we asked: which ecological scenario 
best represented natural co-infections?Vaccine immunity  
To represent vaccine immunity, the proliferation of CTL is only linked to the vaccine-
type, HPV-16. Therefore, the Z equation is    16( )co
dZ P P Z Z
dt
γ μ= + − . 
The vaccine induces a strong humoral immunity response (up to 100 fold the natural antibody 
response (Schiller et al., 2008)), therefore we set w16 to be 100.  Since the virus-like-particles 
(VLP) used in the vaccine are very immunogenic, they effectively induce several immunological 
pathways, which includes initiating helper T-cell responses (Stanley, 2010). Thus, the vaccine 
has been shown to generate a cell-mediated response to the vaccine-targeted protein, L1, and this 
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response can also be cross-reactive with non-vaccine types (Christensen and Bounds, 2010; 
Emeny et al., 2002; Pinto et al., 2006; Weinberg et al., 2012). We assumed the CTL invaded 28 
days post infection. Since no empirical estimate was available for the timing of the onset of the 
vaccine response, we estimated this by considering the slow nature of HPV´s non-lytic 
replication cycle. Squamous epithelial cells require 3 weeks to complete their life cycle (Stanley 
et al., 2006), therefore, we assumed it took at least three weeks plus an extra week for the 
infection to be found and for the immunity to have mounted. Once initiated, the vaccine CTL 
proliferation was 5.6 fold the natural infection  (Pinto et al., 2006), γ = 14 day-1. When the 
vaccine does not elicit a cross-reactive response we set αhr = 0, otherwise αhr < α16.  
With the immunity scenarios we asked: Which scenario gave competitive release, and how does 
the vaccine change the within-host ecology? 
 
 
Results  
Natural Immunity 
Figure 2 summarizes the outcome of a wide range of co-infections for different 
combinations of types that experience no to full cross-reactivity (0 < α16 or hr < 0.5) and that 
experience immunity mounted first against HPV-16 (i) or against the other type (ii). Notice that 
in all these ecological scenarios coexistence is possible for many combinations of types (see the 
regions ‘all coexist’, ‘Phr & Pco’, ‘P16 & Pco’ and ‘P16 & Phr’ regions in Fig. 2), demonstrating 
that coexistence does not solely arise from independence or ‘no interactions’. 
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In the case of independent resource use (Fig. 2a), the outcomes of co-infections with 
types of various replication rates (from none, fhr = 0, to the same replication rate as HPV-16, 
0.4), suggest that related types (strong cross-reactivity: 0.25 < α16 or hr < 0.5) would be pressured 
to have similar replication rates to HPV-16 in order to avoid clearance (see arrow Fig. 2a.i). 
However, less cross-reactive types (αhr < 0.25) can have lower replication rates (fhr < 0.4), and 
still coexist in co-infections (Fig. 2a.i: ‘all coexist’ region), regardless of which type is targeted 
by the immune response. Usually, non-HPV-16 types are found at lower abundances, and to get 
this discrepancy in viral load under independence requires non-HPV-16 types to have different 
intrinsic replication rates (Table 2 A; natural, compare hr for different fhr) and burst sizes, which, 
we believe, has not been quantified. 
HPV-16 infections tend to last longer than infections with other types (Trottier et al., 
2008), yet, it has not been demonstrated that HPV-16 consistently outlasts all other co-infecting 
types. Reconciling this with our results suggests that strong facilitation is unrealistic because it 
allows the non-HPV-16 type to dominate all natural infections (Fig. 2 c, d, ε > 20, in both i and 
ii).  
When independent, both types infect the same fraction of patches (see as an example, < 
300 days in Fig. 3 a.i in A and B) if colonization rates of patches are medium-high. Clinically, 
this would lead to finding co-infecting types just as often as HPV-16 by randomly sampling from 
different regions of the cervix, vagina or vulva, which is not the case. Also, this does not 
coincide with the clustering of types that is often found within patients (e.g. some types are more 
common on the vaginal wall or in mucosal cells (Castle et al., 2007; Hadzisejdć et al., 2007)). 
However, heterogeneous patch use is more characteristic of low colonization rates (not shown) 
and intra-patch competition (Fig. 3 a.ii in A and B).  
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Recent data showed a significant decrease in HPV-16 viral load, but not exclusion, when 
in co-infection with another HR α-9 type (Xi et al., 2009). Here, we compared natural single 
infection and co-infection viral loads of each type, Table 1 and 2 respectively. A viral load drop 
of HPV-16 in co-infection, like that found in Xi et al., happened across both immunity conditions 
(i and ii) and in all competitive and competitive with facilitation scenarios (compare 16 in Table 
1 to Table 2 B and D under ‘weak’). With facilitation and independence, however, HPV-16’s 
viral load could be higher (compare Table 1 to Table 2 A and C under ‘weak’), which is 
inconsistent with (Xi et al., 2009), thus, competition or competition with facilitation best 
represented these findings. 
Finally, in all natural immunity scenarios, HPV-16 did not exclude the other type before 
CTL invasion (e.g. see 0 to 300 days in Fig. 3a in A and B) even if replication rates were very 
different, for example fhr =1 and f16 = 0.01. This is because the non-HPV-16 type can exist within 
co-infected patches, unless intra-patch competition is so high that it cannot reproduce at all fhrco = 
0. This suggests that in all considered interaction scenarios, types can coexist before the adaptive 
immune system invades to clear the infection. Once again, this shows that independence is not 
required for coexistence.  
 
Vaccine Conditions  
Under vaccine conditions, all non- and most weakly cross-reactive types were not cleared 
by the vaccine (the large ‘Phr wins’ regions in Fig. 4 compared to Fig. 2) which corresponds with 
vaccine trials that showed limited cross-protection (Wheeler et al., 2012). From Figure 4 a – c, it 
appears that the underlying within-host interactions play little role in determining whether the 
non-vaccine type is cleared, instead the strength of cross-reactivity best determines whether a 
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type is cleared (αhr > 30). However, if there is both underlying competition and facilitation then 
the strength of facilitation can allow cross-reactive non-vaccine types to escape (Fig. 4 d). 
Finally, if non-vaccine types are similar or more reproductive than HPV-16, then through simple 
competition for empty patches most are able to evade clearance by the vaccine (Fig. 4 e, line).   
The non-vaccine type was able to infect newly available patches, instead of residing 
mostly in co-infected patches (Fig. 3 before 300 days: compare a and b). How quickly the non-
vaccine type filled all available patches depended on the underlying interaction and the strength 
of cross-reactivity (Fig. 3 b in B).  
Whether the new patch dominance of the non-cross-reactive non-vaccine type translated 
to noticeably higher viral loads depended on which natural ecological scenario existed before 
vaccination. Under independence, weak competition and facilitation only the vaccine loads were 
lower, though the decrease depended on the strength of the cross-immunity (A, B, C in Table 2). 
Under strong and moderate competition, the vaccine viral loads were higher (B in Table 2). The 
degree of competitive release depended on the strength of the intra-patch competition and the 
strength of the cross-reactivity. For example, with strong competition (fhrco = 0.02) non-cross-
reactive types doubled their viral load (B in Table 2).  
Since our natural immunity results point to some form of competition as being the most 
likely underlying ecological scenario, then the vaccine could increase viral loads of the non-
vaccine types in co-infected vaccine patients, if they are not cross-reactive with the vaccine. Also 
note that types along the border between clearance and escape (Fig. 4) could experience a strong 
selection pressure to evolve to become less similar to the vaccine type. The arrows in Figure 4 e 
show that if the non-vaccine type evolves to be less immunologically distinct or to have a higher 
replication rate (horizontal and vertical arrows, respectively) then they can escape clearance. 
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Discussion 
The most common hypothesis for HPV type interactions is that they do not interact 
(Dillner et al., 2010; Stanley et al., 2006; Tota et al., 2013, 2011a; Woodman et al., 2007), and so 
far, most vaccine trials have not seen significant increases in prevalence of non-vaccine types 
(Wheeler et al., 2012) which seems to support this independence hypothesis. Similarly, studies 
using odds ratios have concluded that type replacement is not likely because HPV types were 
found to occur randomly and to lead to cervical disease independently (Chaturvedi et al., 2011; 
Palmroth et al., 2012; Rositch et al., 2012; Tota et al., 2013, 2011b).  However, two types have 
been flagged as potentially having a competitive advantage (Merikukka et al., 2011; Tota et al., 
2011a) and a recent study found that the prevalence of non-vaccine types, including high-risk 
types, was indeed higher in vaccinated patients (Kahn et al., 2012). Our study helps reconcile 
these different findings by illustrating that within-host dynamics can give rise to observed 
clinical patterns without invoking independence or facilitation. We propose that we can help 
explain surprising results if we adopt an ecological perspective and if we are mindful of which 
scale we are studying.  
Consider three scales: the tissue (or patch) level, individual hosts, and the host 
population. At the tissue level, there are some suggestions of type interactions. HPV-40 and 
HPV-11 can separate regionally (Christensen et al., 1997), and recently a study showed that 
lesions are caused by only one HPV type (Quint et al., 2012). These results could be explained 
by spatial ecology concepts such as ‘local founder control’ (the first in a patch blocks the other 
from entering) or ‘hierarchical competition’ (the superior local competitor always, quickly or 
slowly, outcompetes the other) (Klausmeier and Tilman, 2002), and thus, should be considered. 
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Indeed, HPV’s highly spatial infection cycle suggests that more complex interactions are at work 
than is appreciated. Common clinical methods (e.g. swabs) are too coarse to see these differences 
in HPV tissue distribution (Mendez et al., 2005; Rousseau et al., 2003) and thus are unlikely to 
find differential uses of space by HPV types. Therefore, there is considerable need for novel 
animal model studies or other experimental approaches to address HPV type interactions at the 
tissue level.  
At the host level, HPV types have consistently been found to co-infect (Plummer et al., 
2011). Here, we have shown that various patch-level interactions can lead to coexistence at the 
host level. Hence, coexistence of types inside a patient does not necessarily imply that types are 
not interacting. This is consistent with ecological findings where competitive interactions 
regularly do not lead to exclusion. In the HPV literature, competitive exclusion is considered the 
ultimate outcome of ‘niche overlap’ (Garnett and Waddell, 2000; Poolman et al., 2008; Tota et 
al., 2013), however, ecological niche theory (Chase and Leibold, 2003; Tilman, 1982) is more 
developed than this and gives several mechanisms for coexistence. Consider four key dimensions 
of a niche: resources, enemies, space, and time (Chesson, 2000). Species (or strains) will differ in 
more than one of these, and trade-offs play an important role in mediating their coexistence 
(Amarasekare, 2009; Chesson, 2000). For example, stable coexistence between strains can be 
due to a trade-off where the advantage of immunity evasion by one strain is balanced by the 
advantage of resource exploitation of the other. Because antigenically similar strains that exploit 
the same host are very common, this trade-off should be investigated more in HPV and in other 
virus studies (Murall et al., 2012). Similarly, differences in the use of space readily allow for 
coexistence (review (Amarasekare, 2003)). Our model shows how this may occur in HPV, 
because patch heterogeneity allowed types to coexist at the host level. Finally, then, our results 
and present day understanding of ecological coexistence suggest that the assumption that the 
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presence of co-infections is evidence of no interactions between types (Kaasila et al., 2009; 
Palmroth et al., 2012) is fallacious. 
Returning to scale, inferring interactions at the population level for HPV, and other 
infectious diseases with regularly co-infecting strains, may not be possible given the 
aforementioned. Indeed, it is proving a difficult task (review (Tota et al., 2013)). Since species 
distributions do not always hint at the underlying local interactions, more direct empirical studies 
at lower scales are needed, and finding competitive interactions will require manipulative 
experiments. Untangling these interactions is very important because the response to a 
perturbation, such as vaccination, will vary widely depending on the underlying mechanism, i.e. 
how types interact.  
It should be noted that ‘no interactions’, or as Hubbell put it “nothing is going on”, is not 
equivalent to conventional ecological ‘neutrality’, where types would still be interacting but their 
effect on each other would be exactly symmetrical and thus their per capita vital rates would not 
differ (Hubbell, 2001). A within-host model that captures neutrality would be inspired by a 
neutral model such as Hubbell (2001), which has been attempted for a multi-strain 
epidemiological model (Lipsitch et al., 2009). Inadvertently, the issue of HPV type interactions 
has landed in the centre of an ecological debate on whether niche or neutral theory best describes 
ecological interactions (Bell, 2001; Chase and Myers, 2011; Gravel et al., 2006; Hubbell, 2001; 
Rosindell et al., 2012). Its resolution should, therefore, be of interest to both the medical and 
ecological communities. Since closer examination of ecological systems often uncovers 
underlying non-neutral interactions (Holt, 2006; McGill et al., 2006), and since many medically 
important viruses are highly competitive (e.g. HIV), conclusively finding independent niches or 
neutrality in HPV would be very interesting indeed.    
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Since our model suggests that some competition is likely, non-vaccine types in 
vaccinated hosts could increase patch use and viral load. To observe this signal, clinical studies 
would be required, e.g. ones that compare the viral loads (preferably longitudinal) of non-vaccine 
types in vaccinated and unvaccinated hosts, in order to capture any niche expansion (or 
contraction). Our model shows that niche expansion could be slight and so we suspect this 
within-host signature will be detectable before there are significant changes in prevalence at the 
population level.  
Polyvalent vaccines are currently being developed against HPV and there is discussion as 
to which types to include (Bosch et al., 2008). Inclusion of all the oncogenic types in the 
polyvalent vaccines would be more effective than depending on weak cross-protection. Our 
model shows that vaccines must elicit a strong cross-reactive response in order to be effective 
against non-vaccine types. One promising approach to achieve this maybe to include the L2 
protein which appears to elicit a broader cross-neutralizing effect (Mariani and Venuti, 2010).  
There are some limitations and caveats to consider. First, this model is not explicitly 
spatial. However, because HPV interact either within or between patches, and disperse to either 
close or far new patches, then this kind of setup is most appropriately modeled by patch models 
(Klausmeier and Tilman, 2002). Second, we did not include a dynamical model of antibodies. 
Our model assumes that the antibody response is constant and so, does not capture the more 
realistic feature of the delay before invasion of the infection area. Thus, our model may be over 
estimating the effect of the vaccine since a delay would benefit the virus to establish a secondary 
infection. Whether this constant assumption or a dynamical approach is needed will depend on 
the empirical measurement of the dynamics of the humoral response directly after a secondary 
infection. Finally, while we assumed that co-infected cells experience additive clearance, it is 
possible that by presenting the antigens of two types, presentation and thus clearance are 
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decreased. If this were true, then it would be advantageous for the viruses to co-infect cells, 
particularly when in a co-infection with immunologically distinct types. This could result in 
more co-infected patches, and potentially longer transients before clearance, as it would be more 
difficult to clear the targeted type as it hides in co-infected patches that act as reservoirs.  
Despite these caveats, mathematical models are often used to help untangle complex 
interactions in ecology and in disease dynamics (Mideo et al., 2008), and are particularly useful 
when there are knowledge gaps. Although our model is a simplification of reality, it is grounded 
in the biology of HPV infections, and so it allowed us to explore the competing hypotheses from 
the literature. 
Though we do not directly address the evolutionary potential of HPV, our results suggest 
that vaccinated hosts could set the stage for some non-vaccine cross-reactive types to escape the 
vaccine response. Vaccine trials have demonstrated that cross-protection is partially effective 
(e.g. 44.8% effective against 6-month persistent HPV-33 infection (Wheeler et al., 2012)), and so 
this ‘leakiness’ might select for variants to escape this new vaccine-induced immune response. 
Our results point to two traits that could allow variants of non-vaccine types to escape: decreased 
epitope similarity, or more alarmingly, increased replication rates. In time, then, vaccine cross-
protection could wane, i.e. ‘cross-immunity escape’, or non-vaccine types could become more 
aggressive. Unfortunately, vaccines have driven other pathogens to increase their replication 
rates (Gandon and Day, 2008). Rapid ecological changes drive evolutionary changes and not 
enough is known about the differences between the natural and vaccine within-host ecology to be 
certain that the vaccine will not select for trait changes in non-vaccine types. 
Currently, our model does not lend itself to model fitting since enumerating infected 
patches from samples is not yet implemented. However, with new methods (e.g. (Quint et al., 
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2012)) it could be possible, and we hope future work will link models with patch data. As we 
move to using more ultrasensitive HPV genotyping assays (Schmitt et al., 2010), we can more 
frequently sample co-infections, in order to better quantify the dynamics of all types in the 
infection. This will help to measure natural vs. vaccine within-host differences; fit models to data 
and hence better tease apart the within-host ecology; see if non-vaccine types in co-infections are 
reciprocally affected by the vaccine types; and, finally, get direct evidence for the duration over 
which vaccinated hosts produce and shed virus relative to unvaccinated hosts. Instead of the 
‘wait and see’ approach of long-term monitoring of type prevalence in vaccinated populations, 
we hope this work will incite new proactive studies. 
More ecologically cognisant HPV studies will help explain whether the vaccine drives or 
avoids an evolutionary ecological response. They will either lead us to remedy the problem of 
type replacement if it appears, or help us understand more mechanistically why the vaccine 
worked. This knowledge can then help us avoid type replacement in future vaccination programs. 
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Figure Legends 
 
Figure 1.  
a) An illustration of layered squamous cell infections; a top-down and cross-section view 
of the epidermis. Free virus particles are released at the surface (i) and need an abrasion 
in the epidermis to reach basal cells to start a new patch (ii).  b) A schematic of the 
model. See methods for description of symbols. 
 
Figure 2.  
Parameter plots: infection outcomes for various ecological scenarios. a) 
Independence. At fhr = 0.4 (dotted line), the two types reproduce at the same rate. In the 
bottom-left quarter of these two plots (below fhr = 0.4 and below α16 or hr = 0.25) the non-
vaccine type has a lower reproductive rate than HPV-16 and the types are weakly cross-
reactive.  b) Intra-patch competition. i. When cross-reactivity is weak (αhr < 0.25) then 
the strength of the intra-patch competition affects the outcome. At fhrco = 0, the intra-patch 
competition is so strong that the other type is excluded from patches altogether. ii. Only 
when intra-patch competition is weak, is the HR type able to evade the immune response 
by hiding in co-infected patches (P16 & Pco region).  c) Facilitation. Facilitation allows 
for large regions of coexistence, even with a small amount of facilitation (1 < ε < 12).  d) 
Facilitation and competition. The inclusion of intra-patch competition shrinks the 
coexistence region, and competition decreases the ability of facilitation to release the 
other type from clearance by the immune system. 
 
 
28 
 
Figure 3.  
Example time-series of natural and vaccine cases (neutral, competition, facilitation).  
A. Types are not cross-reactive.  B. Types are weakly cross-reactive. a) Natural cases. In 
all natural immunity scenarios with interactions (ii and iii) both types coexist until the 
immune invasion (before day 300), i.e. co-infecting patches prevents exclusion of less 
replicative type. Intra-patch competition (ii) gives more heterogeneous patch use and 
HPV-16 dominance, whereas co-infected patches dominate in facilitation case (iii) which 
is unrealistic. b) Under vaccination, non-vaccine types are able to infect all patches once 
the vaccine type is cleared, in A faster than in B.  
 
Figure 4.  
Parameter plots of vaccine conditions: outcomes for various ecological scenarios.   
a) Independence. For non- and weakly cross-reactivity types the vaccine allows for the 
non-vaccine type to infect all patches, regardless of its replication rate.  b) Intra-patch 
competition.  As intra-patch competition increases the clearance region grows slightly. c) 
Facilitation. The vaccine results are independent of facilitation; similar to independence, 
where strength of cross-reactivity determines outcome. d) Facilitation and Competition. 
Combining facilitation and competition shrinks clearance region, allowing the non-
vaccine type to escape. e) Patch competition. Used model A.2. Compared to the neutral 
parameter plot (a) the clearance region is more affected by competition for patches. 
Increasing the replication rate of the non-vaccine type is more effective at allowing the 
type to avoid clearance by the vaccine even if it experiences strong cross-reactivity 
(arrow up). Types that are more cross-reactive could evolve to increase its replication rate 
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to similar or even higher replication rates than HPV-16 to avoid being wiped out by the 
vaccine.  
 
Table 1. 
Mean viral loads: single infection. Mean quantities of free virions produced by patches 
infected by each HPV type when in an infection alone. Made with model A.1. 
Parameters: f16 = 0.4, fhr = see table, α16 or hr = 0.5, e16 or hr=1, w16 or hr = 1, μ = 0.5, γ = 2.5. 
 
Table 2. 
Mean viral loads: co-infection. Mean quantities of free virions produced by all patches 
that contain a particular type per day. These are not meant to represent real measurements 
of viral titers but rather are simply a method of measuring the relative viral loads of 
various hosts. Parameters: see Table A.2 (Appendix).  
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Appendix A 
 
Patch model derivation 
Assume that the first patch of infected cells is established during, or shortly thereafter, physical 
contact (e.g. intercourse) with an infected part of another person’s body. Given that there are a 
number of abrasions in the epithelium, there are now two kinds of patches, a portion of which are 
empty and some that are infected with the HPV type HPV-16, P16. The proportion of empty 
patches is thus 0 161P P= − .  We assume that the proportion of infected patches changes 
dynamically in time, and their creation is due to the infection of empty patches at a rate, e16, by 
the free virions produced by the infected patch, f16. Assuming mass-action and using a similar 
formalism as the Levins’ model (Klausmeier and Tilman, 2002; Levins and Culver, 1971; 
Levins, 1969) we get the equation 16 16 16 16 0
dP
e f P P
dt
=  for the creation of infected patches.  
Since clearance of HPV infection requires CTL invasion (Stanley, 2006), patches are 
only cleared by CTL. A variable that represents the CTL population, Z, is included because CTL 
invasion is a dynamic process. Therefore, a singly infected patch is cleared by the immune 
system at a rate α16. We assume that the abundance of CTL increases proportionally with the 
infected patches. Also to investigate how antibodies decrease the establishment rate of new 
patches by neutralizing free virions, we included the parameter w16. All together this gives a 
patch model of an infection with only HPV-16,  
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16
16 16
16 16 0 16 16
16
0 161
dZ P Z Z
dt
dP e
f P P P Z
dt w
P P
γ μ
α
= −
= −
= −
   (A.1) 
 
Consider now a co-infection case, where two HPV types solely infect their own patches. 
The immune response is only stimulated by one type, i, but can kill the other type, j, if there is 
cross-reactivity (where αj > 0). Thus, model A.1 can be extended then to, 
 
16 16
16 16 0 16 16
16
0
0 161
i
hr hr
hr hr hr hr
hr
hr
dZ PZ Z
dt
dP e
f P P P Z
dt w
dP e
f P P P Z
dt w
P P P
γ μ
α
α
= −
= −
= −
= − −
           (A.2) 
This model assumes that HPV-16 and the other HR type are competing for empty patches, and 
cannot co-infect patches. Note that this model could be altered to represent a within-host 
superinfection scenario. P16 could become Phr and vice versa, by allowing infected patches to 
become infected by the other type and by allowing instantaneous replacement of the resident 
type. We chose not to consider this scenario in our analyses. 
 
To consider independence, we included two empty patch variables,  
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16
16 16
16 16 016 16 16
16
0
016 16
0
1
1
hr hr
hr hr hr hr hr
hr
hr hr
dZ P Z Z
dt
dP e
f P P P Z
dt w
dP e
f P P P Z
dt w
P P
P P
γ μ
α
α
= −
= −
= −
= −
= −
            (A.3) 
Here the two HPV types do not use the same patches, and are completely independent in their 
resource use. If the HPV types are also immunologically distinct, then this model, A.3, 
represents an ‘independent niche’ scenario, which is not consistent with the conventional use of 
the word ‘neutral’ in the ecology literature (see discussion for more).  
 In order to investigate the scenario where patches could be co-infected by both HPV 
types we included the variable, Pco. This implies that free virions of type i (either 16 or hr) are 
now produced by both co-infected patches, Pco, and singly infected patches, Pi, at a rate of fico and 
fi respectively. Thus, the terms that represent viral production,  fiPi, are now replaced by the 
additive term (fi Pi + fico Pco). 
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dP e e
f P f P P
dt w w
γ μ
α
α
= + −
= + − + −
= + − + −
= + + 16 16
0 16
( ) ( )
1
hr hr hrco co hr co
hr co
f P f P P P Z
P P P P
α α+ − +
= − − −
            (A.4) 
where i is either 16 or hr depending on which type is targeted by the immune response. We 
assumed that co-infected patches cannot be created by a single instantaneous event by both HPV-
16 and the other HR type (because it is fairly unlikely that one cell in an empty patch be infected 
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by two different types at exactly the same time), i.e. P0 cannot be come Pco without first being 
P16 or Phr. Therefore, Pco grows only by these two two terms. Also two new establishment rates, 
eij, are needed to capture the establishment of type i into a patch already infected with type j.  
Also, we assumed that co-infected patches cannot become singly infected because a patch can 
contain co-infected cells, and thus CTL cannot remove a single type from co-infected patches.  
Co-infected patches are also removed by CTL, and at the same rates as single infected 
patches, ai or aj. However, since co-infected cells will present antigen from both types, co-
infected patches are assumed to be more visible to the CTL response if the immune response is 
cross-reactive, thus the additive term ߙ16  + αhr in the co-infected patch equation.  
 
To simplify the model, both types are set to have the same establishment rates, e16 = ehr = e.  
Also, we assumed that the positive effect of the presence of one type on the establishment rate of 
the second type is unidirectional, i.e. only the presence of HPV-16 benefits the entry of other 
non-HPV-16 types not vice versa, thus e16 = e16hr = e and ehr ≠ ehr16 = ߝ.. The biological 
mechanism for facilitation is not clear yet (Elbasha and Galvani, 2005) but it is suggested that 
infection of HPV-16 may facilitate infection by another type (Mendez et al., 2005). This stems 
from epidemiological findings of very frequent sequential and concurrent infections where by 
HPV-16 is more common (Rousseau et al., 2001) and is thus potentially facilitating infections by 
other less common types. Therefore, we consider facilitation (positive effect in one direction) 
and not mutualism (reciprocal positive effect). Note then that because the HR type more readily 
enters patches already infected with HPV-16 this implies ߝ  > e. 
Together, this gives the final version of the model used for analysis of different interaction 
scenarios (except independence) under natural immunity,  
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This is model 1 in the methods section.  
Note that the terms (fi Pi + fico Pco) are measures of viral load in these scenarios, because 
(fi Pi + fico Pco) is the total number of type i virions produced by patches Pi and Pij at one time 
step. We used these terms to calculate viral loads for the various ecological scenarios. 
 
Parameter considerations 
When comparing vaccination to natural immunity, we assumed the vaccine’s cross-
reactivity scaled linearly in strength, e.g. if the natural cross-reactive attack rate against the non-
vaccine type is α2 = 0.1, and if the vaccine is 100 times stronger, then the vaccine cross-reactive 
attack rate is α2 = 10. This then assumes that non-vaccine types in vaccinated hosts experience 
stronger cross-reactive immune response, and therefore, we considered the region 0 < α2 < 50 in 
the vaccine parameter plots. If we had not made this assumption then we would consider a very 
small region of the vaccine plots (α2 < 0.5). 
Initial conditions were chosen to be as realistic as possible to the initiation of an 
infection.   Initial P16 and Phr were set to be the same and small (P16(0) = Phr(0) = 0.01) to 
represent the initial colonization of patches (without giving either strain an advantage). Pco was 
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set to zero because it is unlikely they immediately infect the same patch. Finally at the time of 
immunity invasion, one CTL invades (Z(0) =1). We considered how changing some of these 
initial conditions could change results. First we found that increasing initial Z implied that CTL 
would invade much sooner, which is unrealistic for HPV infections. Also, higher initial Z also 
lead to vaccine results where almost all non-vaccine types (even weakly cross-reactive) would be 
cleared by the vaccine. This is also unrealistic since vaccine trials show that only some related 
types are cross-protected against. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A.1: Parameter restrictions and ranges (for types i and j) 
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Strain parameters 
 
e  and ε 
   
establishment 
rate 
 
When e =1, then every time a virion encounters a patch it establishes 
successfully. We assume facilitation when ε > e and when entry into P16 is 
easier than into P0 for the HR type, thus ε > 1. There is no reason to believe 
that HPV-16 blocks entry of the other type (i.e. ε cannot be less than e). 
Overall then ε ≥ 1. 
 
 
fi  and fij 
 
rates of 
virion 
production 
by strains 
inside 
patches alone 
and together 
 
 
If fi = 1, then one virion is made per patch/unit time. 
If fi > 1, then more than one virion is made per patch/unit time. 
And, if 0 ≤ fi < 1, then less than one virion is made per patch/unit time. 
Therefore, virion production rates should be fi ≥ 0 and fij ≥ 0. 
However, given that there are many cells per patch, at least one cell will burst 
at any given time, this implies that fi >1 and fij > 1. 
 
Immunity parameters* 
 
αi 
 
CTL killing 
rate 
 
If αi = 1, then CTL killing is 100% successful, i.e. each CTL removes one 
patch per unit time. 
If 0 ൑ αi ൑ 1, then one CTL removes less than one patch per unit time. 
If αi  > 1 , then each CTL removes >1 patch per unit time. 
We assume CTL are not completely efficient, i.e.  0 ൑ αi  ൑ 1, in the natural 
immunity cases.  
[Note: this does not mean that one CTL does not kill >1 patch in its lifespan it 
just does not necessarily kill 1 patch at every single time step.] 
 
 
wi 
 
strength of 
neutralizing 
antibodies 
 
 
When wi =1 there is no antibody response. 
When wi >1, then wi decreases the rate of establishment. 
 
 
 
 
 
 
 
 
 
 
Table A.2: Parameters used for figures and tables 
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 Parameters 
Model 
used 
in all 
subplots in specific subplots 
Figure 2 
f16 = 0.4 
γ = 2.5 
μ = 0.5  
w16 =1 
whr =1 
e = 1 
 
 
 
 
 
(i) 
α16 = 0.5  
α hr varies from 0 to 0.5 
 
(a) 
 
fhr varies from 0 to 0.8 
e16 = ehr =1 
A.3 
(b) 
 
fhr = 0.2 
f16co = 0.2 
fhrco varies from 0 to 0.2 
ε = 1 
A.5 
 
 
(ii) 
αhr = 0.5  
α 16 varies from 0 to 0.5 
 
(c) 
fhr = 0.2 
f16co = 0.4 
fhrco = 0.2 
ε varies from 1 to 51   
(d) 
 
fhr = 0.2 
f16co = 0.2 
fhrco = 0.05  
ε varies from 1 to 51   
Figure 3 
f16 = 0.4 
fhr = 0.2 
μ = 0.5 
e = 1 
 
 
 
A 
(a) natural:   
 γ = 2.5 
α16 = 0.5 
α hr = 0 
w16 = whr =1 
 
(b) vaccine:  
γ = 14 
α16 = 50 
α hr = 0 
w16 =100 
whr =1 
(i) e16 = ehr =1 A.3 
(ii) 
f16co = 0.2  
fhrco = 0.05 
ߝ =1 A.5 
 
B 
Same as in A except: 
(a) natural: 
α hr = 0.05 
 
(b) vaccine:  
α hr = 5 
whr =10 
(iii) 
f16co = 0.4  
fhrco = 0.2 
ߝ  = 34 
Figure 4 
 
f16 = 0.4  
α16 = 50 
αhr varies from 
0 to 50 
 
γ = 14 
μ = 0.5 
w16 = 100 
whr = 2(αhr) 
e = 1 
 
  
(a) fhr varies from 0 to 0.8 e16 = ehr =1 
A.3 
(b) 
fhr = 0.2 
f16co = 0.2 and  fhrco varies from 0 to 0.2 
ε = 1  
A.5 
 (c) 
fhr = 0.2 
f16co = 0.4 and  fhrco = 0.2 
ε varies from 1 to 51    
(d) 
fhr = 0.2 
f16co = 0.2 and  fhrco = 0.05  
ε varies from 1 to 51   
(e) fhr varies from 0 to 0.8 e16 = ehr =1 
A.2 
Table 2. 
f16 = 0.4  
μ = 0.5 
e = 1 
 
Natural 
γ = 2.5, w16 and hr = 1 
none: 
if αi = 0.5, then αj = 0  
weak: 
if αi = 0.5, then αj = 0.2 
 
Vaccine 
γ = 14, α16 = 50, w16 =100 
none: 
αhr = 0 
 whr = 1 
weak: 
αhr = 20 
whr = 40 
A fhr see table e16 = ehr =1 
A.3 
B 
fhr = 0.2 
fhrco see table  
f16co = 0.2 
ε = 1 
A.5 
 
C, D 
fhr = 0.2 
f16co = 0.4 in C and = 0.2 in D 
fhrco = 0.2 in C and = 0.05 in D  
ε see table 
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Table 1. 
 
    Natural 
    against 16  against HR 
16    190.3  ‐ 
       
hr  fhr     
  0.35  ‐  166.2 
  0.2  ‐  94.0 
  0.05  ‐  21.8 
 
Table 2. 
 
        Natural  Vaccine 
        i. against 16  ii. against HR   
cross‐reactivity:   none  weak  none  weak  none  weak 
A    fhr               
Neutrality    0.35  16  186.7  187.7  234.6  230.4  2.3  2.3 
      hr  204.8  199.9  162.8  162.8  112.5  12.4 
                 
    0.2  16  186.7  186.7  234.6  232.1  2.3  2.3 
      hr  115.1  110.3  91.0  91.0  63.4  6.2 
                 
    0.05  16  186.7  186.7  234.6  233.8  2.3  2.3 
      hr  25.6  21.5  19.3  19.3  14.5  0.6 
                   
B    fhrco                
Intra‐patch   strong  0.02  16  109.0  120.5  165.5  164.3  1.3  1.9 
Competition    hr  32.2  7.1  7.1  7.1  61.0  6.7 
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  moderate  0.1  16  92.3  130.7  149.2  147.8  1.3  1.9 
      hr  68.3  42.2  41.8  41.8  61.2  6.7 
                   
  weak  0.18  16  90.2  101.2  147.3  145.8  1.3  1.9 
      hr  103.7  78.7  76.6  76.6  61.5  6.7 
                   
C    ε                
Facilitation  moderate  34  16  175.2  175.2  231.7  230.5  1.8  1.9 
      hr  115.5  114.0  88.3  88.3  62.5  8.1 
                   
  weak  6  16  175.2  186.7  232.7  231.2  1.8  1.9 
      hr  115.1  97.4  87.8  87.7  62.1  6.9 
                   
D    ε                
Facilitation  moderate  34  16  86.1  86.0  142.1  140.9  0.9  1.7 
(with      hr  48.8  47.4  22.8  22.8  61.3  7.8 
Competition)                   
  weak  6  16  88.0  99.0  144.2  143.0  1.0  1.8 
        hr  48.2  22.8  22.3  22.2  61.2  6.8 
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Highlights 
• With a model we evaluated competing hypotheses of HPV type interactions 
• Independence and facilitation are not necessary for coexistence of types inside hosts 
• Spatial heterogeneity can lead to underappreciated complex type-type interactions 
• Conditions for type replacement are possible at the within-host level 
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